Time is of the essence: Coupling sleep-wake and circadian neurobiology to the antidepressant effects of ketamine
This theory-building paper (2020) proposes that the circadian rhythm may be an important factor in the antidepressant effect of ketamine therapies.
Authors
- Kohtala, S.
- Alitalo, O.
- Rosenholm, M.
Published
Abstract
Several studies have demonstrated the effectiveness of ketamine in rapidly alleviating depression and suicidal ideation. Intense research efforts have been undertaken to expose the precise mechanism underlying the antidepressant action of ketamine; however, the translation of findings into new clinical treatments has been slow. This translational gap is partially explained by a lack of understanding of the function of time and circadian timing in the complex neurobiology around ketamine. Indeed, the acute pharmacological effects of a single ketamine treatment last for only a few hours, whereas the antidepressant effects peak at around 24 hours and are sustained for the following few days. Numerous studies have investigated the acute and long-lasting neurobiological changes induced by ketamine; however, the most dramatic and fundamental change that the brain undergoes each day is rarely taken into consideration. Here, we explore the link between sleep and circadian regulation and rapid-acting antidepressant effects and summarize how diverse phenomena associated with ketamine’s antidepressant actions - such as cortical excitation, synaptogenesis, and involved molecular determinants - are intimately connected with the neurobiology of wake, sleep, and circadian rhythms. We review several recently proposed hypotheses about rapid antidepressant actions, which focus on sleep or circadian regulation, and discuss their implications for ongoing research. Considering these aspects may be the last piece of the puzzle necessary to gain a more comprehensive understanding of the effects of rapid-acting antidepressants on the brain.
Research Summary of 'Time is of the essence: Coupling sleep-wake and circadian neurobiology to the antidepressant effects of ketamine'
Introduction
Kohtala and colleagues frame their review around an important translational gap in ketamine research: although ketamine produces rapid antidepressant effects within hours and sustained benefits that peak about 24 hours after a single dose, mechanistic insights from molecular and animal studies have not translated efficiently into improved, reliably sustained clinical treatments. Earlier research has identified multiple molecular and synaptic mechanisms implicated in ketamine's action—NMDAR blockade, glutamate bursts, AMPAR activation, BDNF-TrkB signalling, mTOR/ERK pathways and synaptogenesis—but these pharmacological explanations do not account for the mismatch between ketamine's short-lived acute pharmacology and its delayed, longer-lasting clinical benefits. This review sets out to examine how sleep and circadian biology intersect with the neurobiology of ketamine's rapid antidepressant effects. The authors propose that daily physiological processes—particularly sleep homeostasis and circadian timing—may be critical to understanding how transient pharmacological perturbations produce longer-term changes in mood and neural circuits. They therefore review basic sleep and circadian mechanisms, summarise evidence linking these systems to ketamine's molecular and systems-level effects, and discuss recently proposed hypotheses that explicitly couple sleep/circadian processes to rapid-acting antidepressant action.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Compound
- Topics
- APA Citation
Kohtala, S., Alitalo, O., Rosenholm, M., Rozov, S., & Rantamäki, T. (2021). Time is of the essence: Coupling sleep-wake and circadian neurobiology to the antidepressant effects of ketamine. Pharmacology & Therapeutics, 221, 107741. https://doi.org/10.1016/j.pharmthera.2020.107741
References (13)
Papers cited by this study that are also in Blossom
Abdallah, C. G., Averill, L. A., Collins, K. A. et al. · Neuropsychopharmacology (2016)
Abdallah, C. G., Averill, L. A., Gueorguieva, R. et al. · Neuropsychopharmacology (2020)
Abdallah, C. G., Sanacora, G., Duman, R. S. et al. · Chronic Stress (2018)
Berman, R. M., Cappiello, A., Anand, A. et al. · Biological Psychiatry (2000)
Kishimoto, T., Chawla, J. M., Hagi, K. et al. · Psychological Medicine (2016)
Li, C. T., Chen, M. H., Lin, W. C. et al. · Human Brain Mapping (2016)
Murrough, J. W., Iosifescu, D. V., Chang, L. C. et al. · American Journal of Psychiatry (2013)
Nagele, P., Duma, A., Kopec, M. et al. · Biological Psychiatry (2015)
Newport, D. J., Carpenter, L. L., Mcdonald, W. M. et al. · American Journal of Psychiatry (2015)
Nugent, A. C., Ballard, E. D., Gould, T. D. et al. · Molecular Psychiatry (2018)
Show all 13 referencesShow fewer
Yang, Y., Cui, Sang, K. et al. · Nature (2018)
Zanos, P., Gould, T. D. · Molecular Psychiatry (2018)
Zanos, P., Moaddel, P. J., Morris, P. J. et al. · Nature (2016)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.